Relationship between the expression of VEGF signal components and matrix metalloproteinases in ovarian tumorsстатья
Информация о цитировании статьи получена из
Web of Science ,
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 23 сентября 2021 г.
Авторы:
Gershtein E.S. ,
Kushlinsky D.N. ,
Levkina N.V. ,
Tereshkina I.V. ,
Nosov V.B. ,
Laktionov K.P. ,
Adamyan L.V.
Журнал:
Bulletin of Experimental Biology and Medicine
Том:
151
Номер:
4
Год издания:
2011
Издательство:
Springer Nature
Местоположение издательства:
Switzerland
Первая страница:
449
Последняя страница:
453
DOI:
10.1007/s10517-011-1353-5
Аннотация:
The content of vascular endothelium growth factor is signifi cantly increased, while the level of matrix metalloproteinase-2 is 2-fold reduced in ovarian cancer tissue compared to benign tumors. A trend to an increase in the levels of matrix metalloproteinases 7 and 9 and reduction of vascular endothelial growth factor type 2 receptors in tumor tissue was also detected. A highly signifi cant negative correlation between the levels of vascular endothelial growth factor and matrix metalloproteinase 2 and positive correlations between vascular endothelial growth factor and matrix metalloproteinase 7, vascular endothelial growth factor and matrix metalloproteinase 9, matrix metalloproteinase 2 and vascular endothelial growth factor type 2 receptors were revealed. In the tumors assayed after preoperative therapy, relative normalization of the studied parameters was observed: the level of vascular endothelial growth factor decreased signifi cantly, while the levels of matrix metalloproteinase 2 and vascular endothelial growth factor type 2 receptors increased. The levels of the markers differed signifi cantly in ovarian tumors of different histological types, and the levels of vascular endothelial growth factor type 2 receptors were higher in patients with stage III compared to stage I and the content of matrix metalloproteinase 7 was higher in stage III compared to stage II cancer. В© 2011 Springer Science+Business Media, Inc.
Добавил в систему:
Герштейн Елена Сергеевна